Skip to main content
NIH funding notice RFA-AI-17-028

Next Generation Multipurpose Prevention Technologies (NGM) (R61/R33 Clinical Trial Optional)

Closed on March 19, 2018.

Posted
September 12, 2017
Close date
March 19, 2018
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,403,885 in first-year total cost, median $1,201,943.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 AL-A (S1)]2

Most frequent institutions

  1. EASTERN VIRGINIA MEDICAL SCHOOL1
  2. MAGEE-WOMEN'S RES INST AND FOUNDATION1
Competing awards under RFA-AI-17-028 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019Long Acting Film Technology for Contraception and HIV Prevention (LATCH)1R61AI142687-01ROHAN, LISA CENCIAMAGEE-WOMEN'S RES INST AND FOUNDATION, PA$1,350,893ZAI1
2019Project Horizon: Hydrogel Injectable Depot System for Next-Generation Long-Acting HIV Prevention and Contraception1R61AI142685-01CLARK, MEREDITH REASTERN VIRGINIA MEDICAL SCHOOL, VA$1,052,992ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-AI-17-028: Next Generation Multipurpose Prevention Technologies (NGM) (R61/R33 Clinical Trial Optional) | ScienceDex | ConductScience